LISATA THERAP.INC.DL-001 (F:8NE) — Stock Price
LISATA THERAP.INC.DL-001 (F:8NE) is currently trading at €0.79 EUR, down 1.25% today. Over the past 52 weeks, shares have ranged between €0.74 and €4.34. This page tracks LISATA THERAP.INC.DL-001's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 8NE market cap.
LISATA THERAP.INC.DL-001 (8NE) Stock Price Chart — Daily History & Trading Volume
The chart below tracks LISATA THERAP.INC.DL-001's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
LISATA THERAP.INC.DL-001 Income Statement — Revenue, Profit & Earnings by Year
LISATA THERAP.INC.DL-001's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €170.00K | €1.00 Million | €0.00 | €0.00 | €0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €7.95 Million | €11.33 Million | €12.73 Million | €43.46 Million | €17.58 Million |
| SG&A | €10.43 Million | €12.07 Million | €12.97 Million | €14.14 Million | €11.47 Million |
| Total Operating Expenses | €18.38 Million | €23.41 Million | €25.71 Million | €57.60 Million | €29.05 Million |
| Operating Income | €-18.21 Million | €-22.41 Million | €-25.71 Million | €-57.60 Million | €-29.05 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Before Tax | €-17.55 Million | €-20.78 Million | €-23.17 Million | €-56.70 Million | €-28.97 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-16.59 Million | €-19.98 Million | €-20.84 Million | €-54.23 Million | €-27.47 Million |
LISATA THERAP.INC.DL-001 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes LISATA THERAP.INC.DL-001's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €17.74 Million | €35.00 Million | €54.69 Million | €73.03 Million | €97.01 Million |
| Total Current Assets | €17.70 Million | €34.58 Million | €53.92 Million | €71.88 Million | €96.18 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €0.00 | €15.04 Million | €27.94 Million | €37.07 Million | €70.32 Million |
| Net Receivables | €0.00 | €900.00K | €0.00 | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €3.14 Million | €5.68 Million | €6.80 Million | €6.71 Million | €5.01 Million |
| Total Current Liabilities | €3.07 Million | €5.61 Million | €6.59 Million | €6.38 Million | €4.52 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €14.86 Million | €29.57 Million | €48.15 Million | €66.58 Million | €92.25 Million |
| Retained Earnings | €-564.65 Million | €-548.07 Million | €-528.08 Million | €-507.24 Million | €-453.02 Million |
LISATA THERAP.INC.DL-001 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how LISATA THERAP.INC.DL-001 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-15.95 Million | €-19.36 Million | €-20.03 Million | €-21.17 Million | €-22.25 Million |
| Capital Expenditures | €28.00K | €0.00 | €0.00 | €285.00K | €60.00K |
| Free Cash Flow | €-15.98 Million | €-19.36 Million | €-20.03 Million | €-21.45 Million | €-22.30 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €599.00K | €-206.00K | €385.00K | €-224.00K | €85.28 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €1.23 Million | €1.65 Million | €2.04 Million | €2.64 Million | €2.00 Million |
| Depreciation | €146.00K | €174.00K | €189.00K | €69.00K | €55.00K |
| Change in Cash | €-253.00K | €-6.38 Million | €-9.56 Million | €7.51 Million | €8.13 Million |
LISATA THERAP.INC.DL-001 Earnings History — EPS Actual vs. Analyst Estimates
Track LISATA THERAP.INC.DL-001's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 15, 2026 | — | — | — |
| Feb 26, 2026 | — | -0.51 | — |
| Nov 06, 2025 | — | -0.53 | — |
| May 07, 2025 | — | — | — |
| Feb 26, 2025 | — | — | — |
| Nov 01, 2024 | — | — | — |